当前位置: 首页 >> 检索结果
4259. Cancer Screening after the Adoption of Paid-Sick-Leave Mandates.
作者: Kevin Callison.;Michael F Pesko.;Serena Phillips.;Julie A Sosa.
来源: N Engl J Med. 2023年388卷9期824-832页
By the end of 2022, nearly 20 million workers in the United States have gained paid-sick-leave coverage from mandates that require employers to provide benefits to qualified workers, including paid time off for the use of preventive services. Although the lack of paid-sick-leave coverage may hinder access to preventive care, current evidence is insufficient to draw meaningful conclusions about its relationship to cancer screening.
4260. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
作者: Sapna P Patel.;Megan Othus.;Yuanbin Chen.;G Paul Wright.;Kathleen J Yost.;John R Hyngstrom.;Siwen Hu-Lieskovan.;Christopher D Lao.;Leslie A Fecher.;Thach-Giao Truong.;Jennifer L Eisenstein.;Sunandana Chandra.;Jeffrey A Sosman.;Kari L Kendra.;Richard C Wu.;Craig E Devoe.;Gary B Deutsch.;Aparna Hegde.;Maya Khalil.;Ankit Mangla.;Amy M Reese.;Merrick I Ross.;Andrew S Poklepovic.;Giao Q Phan.;Adedayo A Onitilo.;Demet G Yasar.;Benjamin C Powers.;Gary C Doolittle.;Gino K In.;Niels Kokot.;Geoffrey T Gibney.;Michael B Atkins.;Montaser Shaheen.;James A Warneke.;Alexandra Ikeguchi.;Jose E Najera.;Bartosz Chmielowski.;Joseph G Crompton.;Justin D Floyd.;Eddy Hsueh.;Kim A Margolin.;Warren A Chow.;Kenneth F Grossmann.;Eliana Dietrich.;Victor G Prieto.;Michael C Lowe.;Elizabeth I Buchbinder.;John M Kirkwood.;Larissa Korde.;James Moon.;Elad Sharon.;Vernon K Sondak.;Antoni Ribas.
来源: N Engl J Med. 2023年388卷9期813-823页
Whether pembrolizumab given both before surgery (neoadjuvant therapy) and after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant therapy alone, would increase event-free survival among patients with resectable stage III or IV melanoma is unknown.
|